Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 226 results for headache

  1. Eptinezumab for preventing migraine (TA871)

    Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.

  2. Infliximab for acute exacerbations of ulcerative colitis (TA163)

    Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.

  3. Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)

    Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.

  4. Ultrasound-guided foam sclerotherapy for varicose veins (IPG440)

    Evidence-based recommendations on ultrasound guided foam sclerotherapy for varicose veins. This involves mixing a chemical with air or another gas to produce a foam, which is injected into the affected vein using ultrasound imaging to monitor its progress.

  5. Endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms (IPG658)

    Evidence-based recommendations on endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms in adults. This involves inserting a wire-mesh device into the aneurysm to act as a plug when a blood clot forms inside it.

  6. Hypertension in pregnancy (QS35)

    This quality standard covers diagnosing and managing hypertension (high blood pressure) and pre-eclampsia during pregnancy, labour and birth. It also covers advice for women with hypertension who may become pregnant and postnatal care for women who have had hypertension or pre-eclampsia. It describes high-quality care in priority areas for improvement.

  7. Photodynamic therapy for brain tumours (IPG290)

    Evidence-based recommendations on photodynamic therapy for brain tumours. This involves giving the patient a drug that makes the tissue sensitive to light and then activating it with a laser light source to destroy the tumour cells.

  8. Transcranial magnetic stimulation for auditory hallucinations (IPG680)

    Evidence-based recommendations on transcranial magnetic stimulation for auditory hallucinations. This involves stimulating the brain with pulses of electromagnetic energy.

  9. Leukapheresis for inflammatory bowel disease (IPG126)

    Evidence-based recommendations on leukapheresis for inflammatory bowel disease. This involves removing a small number of white blood cells from the person’s blood.

  10. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

    Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.

  11. Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)

    Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated

  12. Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)

    Summary of the evidence on delafloxacin for community-acquired pneumonia in adults

  13. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.

  14. Pizotifen to prevent recurrent migraine:- Is pizotifen a clinically and cost effective prophylactic treatment for recurrent migraine?

    of migraine used should be that in the International classification of headache disorders II or this guideline. Outcomes should include...

  15. Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)

    Summary of the evidence on antimicrobial prescribing: delafloxacin